Vlasov A P, Markin O V, Romanov D A, Shukshin A N, Ali Fuad F A, Muhammad A S, Shilov A A
N.P. Ogarev Mordovia State University, Saransk, Russia.
Khirurgiia (Mosk). 2022(9):85-90. doi: 10.17116/hirurgia202209185.
On the basis of a comprehensive assessment of the functional state of the intestine in acute mechanical small bowel obstruction, to justify adequate schemes of its protection.
A clinical and laboratory study of 48 patients with acute small bowel obstruction developed against the background of abdominal adhesions, strangulated abdominal hernia was conducted. The first group (=25) of patients who underwent laparotomy, removal of intestinal obstruction (adhesiolysis and/or herniation, hernial gate plastic surgery), intestinal intubation, standardized therapy after surgery. The second group (=23) - patients, therapy included Remaxol (Polysan Pharmaceutical Plant, Petersburg): 400.0 enterally intraoperatively through a probe after nasointestinal intubation, evacuation of stagnant contents and intestinal lavage with isotonic saline solution; 400.0 - intravenously for 5 days. A number of indicators of homeostasis (endogenous intoxication, oxidative stress), structural and functional state of the intestine were evaluated.
It was found that the inclusion of remaxol in complex therapy (intraoperatively and in the early postoperative period) leads to the optimization of the treatment process of patients with acute intestinal obstruction. The number of complications according to the Clavien-Dindo classification decreased from 17 (first) up to 5 (second group) (χ=3.988, =0.046). Hospital stay decreased from 12.8±1.1 to 10.1±0.8 bed days (<0.05). The effectiveness of the developed scheme is based on its ability to correct the phenomena of enteral distress syndrome relatively quickly, which was confirmed by laboratory and instrumental methods. The most important manifestation of this was a significant decrease in the phenomena of endogenous intoxica tion against the background of a significant decrease in the activity of peroxidation of membrane lipids - triggers of catabolic intestinal lesions.
Studies document the effectiveness of the developed treatment regimen for patients with acute intestinal obstruction. The inclusion of remaxol parenterally and enterally makes it possible to significantly optimize the course of the early postoperative period. One of the main objects of its implementation was the relatively rapid restoration of intestinal function, reduction of manifestations of enteral distress syndrome. This provided rapid relief of endogenous intoxication and, as a result, prevented the progression of the systemic inflammatory response syndrome, which together determined the optimization of the early postoperative period.
在对急性机械性小肠梗阻时肠道功能状态进行全面评估的基础上,论证其恰当的保护方案。
对48例因腹部粘连、绞窄性腹疝引发急性小肠梗阻的患者进行临床和实验室研究。第一组(=25例)患者接受剖腹手术,解除肠梗阻(粘连松解和/或疝修补、疝门整形手术),进行肠道插管,并在术后进行标准化治疗。第二组(=23例)患者,治疗包括使用雷马克索(圣彼得堡的波利索恩制药厂生产):术中经鼻肠插管后通过探头肠内给予400.0,排出停滞内容物并用等渗盐水进行肠道灌洗;术后5天静脉给予400.0。评估了多项内环境稳态指标(内源性中毒、氧化应激)以及肠道的结构和功能状态。
发现将雷马克索纳入综合治疗(术中及术后早期)可优化急性肠梗阻患者的治疗过程。根据克莱文 - 迪诺分类法,并发症数量从第一组的17例减少至第二组的5例(χ=3.988,P=0.046)。住院天数从12.8±1.1天降至10.1±0.8天(P<0.05)。所制定方案的有效性基于其能够较快纠正肠内窘迫综合征现象的能力,这一点通过实验室和仪器方法得到了证实。其中最重要的表现是在内源性中毒现象显著减少的同时,膜脂过氧化活性(肠道分解代谢性病变的触发因素)也显著降低。
研究证明了所制定的急性肠梗阻患者治疗方案的有效性。肠内和肠外使用雷马克索能够显著优化术后早期病程。其实施的主要目标之一是相对快速地恢复肠道功能,减轻肠内窘迫综合征的表现。这迅速缓解了内源性中毒,从而防止了全身炎症反应综合征的进展,共同决定了术后早期病程的优化。